ECSP045179A - Tibolona en el tratamiento de desórdenes asociados con la administración de fármacos que previenen la síntesis del estrógeno endógeno - Google Patents
Tibolona en el tratamiento de desórdenes asociados con la administración de fármacos que previenen la síntesis del estrógeno endógenoInfo
- Publication number
- ECSP045179A ECSP045179A EC2004005179A ECSP045179A ECSP045179A EC SP045179 A ECSP045179 A EC SP045179A EC 2004005179 A EC2004005179 A EC 2004005179A EC SP045179 A ECSP045179 A EC SP045179A EC SP045179 A ECSP045179 A EC SP045179A
- Authority
- EC
- Ecuador
- Prior art keywords
- estrogen
- disorders
- drugs
- treatment
- tibolone
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 title abstract 2
- 229960001023 tibolone Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229940011871 estrogen Drugs 0.000 abstract 4
- 239000000262 estrogen Substances 0.000 abstract 4
- 210000000481 breast Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229940046844 aromatase inhibitors Drugs 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02075235 | 2002-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045179A true ECSP045179A (es) | 2004-08-27 |
Family
ID=27589110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005179A ECSP045179A (es) | 2002-01-22 | 2004-07-06 | Tibolona en el tratamiento de desórdenes asociados con la administración de fármacos que previenen la síntesis del estrógeno endógeno |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050124592A1 (enExample) |
| EP (1) | EP1469861A1 (enExample) |
| JP (1) | JP2005518412A (enExample) |
| KR (1) | KR20040073572A (enExample) |
| CN (1) | CN1620298A (enExample) |
| BR (1) | BR0306789A (enExample) |
| CA (1) | CA2472240A1 (enExample) |
| EC (1) | ECSP045179A (enExample) |
| HR (1) | HRP20040635A2 (enExample) |
| IL (1) | IL162769A0 (enExample) |
| IS (1) | IS7338A (enExample) |
| MX (1) | MXPA04007071A (enExample) |
| PL (1) | PL371181A1 (enExample) |
| RU (1) | RU2004125594A (enExample) |
| WO (1) | WO2003061665A1 (enExample) |
| ZA (1) | ZA200405262B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302572D0 (en) | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE63051B1 (en) * | 1989-03-18 | 1995-03-22 | Akzo Nv | Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one |
| DE69418744T2 (de) * | 1993-03-05 | 1999-11-11 | Akzo Nobel N.V., Arnheim/Arnhem | Verwendung von Pregnanderivaten zur Behandlung von Tumoren |
| EP1102755B1 (en) * | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
-
2003
- 2003-01-16 EP EP20030731620 patent/EP1469861A1/en not_active Withdrawn
- 2003-01-16 MX MXPA04007071A patent/MXPA04007071A/es not_active Application Discontinuation
- 2003-01-16 US US10/502,444 patent/US20050124592A1/en not_active Abandoned
- 2003-01-16 KR KR10-2004-7011160A patent/KR20040073572A/ko not_active Withdrawn
- 2003-01-16 CA CA002472240A patent/CA2472240A1/en not_active Abandoned
- 2003-01-16 RU RU2004125594/14A patent/RU2004125594A/ru not_active Application Discontinuation
- 2003-01-16 IL IL16276903A patent/IL162769A0/xx unknown
- 2003-01-16 BR BR0306789-0A patent/BR0306789A/pt not_active IP Right Cessation
- 2003-01-16 PL PL03371181A patent/PL371181A1/xx not_active Application Discontinuation
- 2003-01-16 HR HR20040635A patent/HRP20040635A2/hr not_active Application Discontinuation
- 2003-01-16 CN CNA038025108A patent/CN1620298A/zh active Pending
- 2003-01-16 JP JP2003561609A patent/JP2005518412A/ja active Pending
- 2003-01-16 WO PCT/EP2003/000373 patent/WO2003061665A1/en not_active Ceased
-
2004
- 2004-06-28 IS IS7338A patent/IS7338A/is unknown
- 2004-07-01 ZA ZA2004/05262A patent/ZA200405262B/en unknown
- 2004-07-06 EC EC2004005179A patent/ECSP045179A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL371181A1 (en) | 2005-06-13 |
| EP1469861A1 (en) | 2004-10-27 |
| ZA200405262B (en) | 2005-08-31 |
| HRP20040635A2 (en) | 2004-10-31 |
| WO2003061665A1 (en) | 2003-07-31 |
| US20050124592A1 (en) | 2005-06-09 |
| CA2472240A1 (en) | 2003-07-31 |
| MXPA04007071A (es) | 2004-10-29 |
| IS7338A (is) | 2004-06-28 |
| BR0306789A (pt) | 2004-12-28 |
| CN1620298A (zh) | 2005-05-25 |
| IL162769A0 (en) | 2005-11-20 |
| KR20040073572A (ko) | 2004-08-19 |
| RU2004125594A (ru) | 2005-03-10 |
| JP2005518412A (ja) | 2005-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068702A1 (es) | Composiciones farmaceuticas | |
| ECSP23096498A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| MX2017011280A (es) | Terapia neuro-afectiva regional topica con cannabinoides. | |
| Magnowska et al. | Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy | |
| JP2020509024A5 (enExample) | ||
| PH12021551023A1 (en) | Methods for shrinking pituitary tumors | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| TW200501945A (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
| Griffin et al. | Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy | |
| ECSP045179A (es) | Tibolona en el tratamiento de desórdenes asociados con la administración de fármacos que previenen la síntesis del estrógeno endógeno | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
| Koltyn et al. | Changes in mood state following whole-body hyperthermia | |
| Bosco et al. | An integrated approach with homeopathic medicine and electro-acupuncture in anaesthesiology during breast cancer surgery | |
| Guo et al. | Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway | |
| WO2022046452A3 (en) | Nanoparticulate system for delivery of pain relief agents | |
| ES2272555T3 (es) | Composicion de estrogeno y otras hormonas con ascorbato, lisina, prol ina y otras sustancias. | |
| Kizilbash et al. | CTNI-23. Preliminary safety and pharmacokinetics data for A phase 1b trial of telaglenastat in combination with radiation therapy and temozolomide in patients with idh-mutant grade 2/3 astrocytoma (Nci-10218) | |
| Modestin et al. | Haloperidol in Acute Schizophrenic Inpatients A Double-blind Comparison of Two Dosage Regimens | |
| Fiore et al. | Radiotherapy and vascular endothelial growth factor receptor-tyrosine kinase inhibitors in renal cancer | |
| AR063712A1 (es) | Tratamiento del dolor usando satraplatino | |
| Viscusi et al. | HTX-011, a proprietary, extended-release combination of bupivacaine and meloxicam, reduces acute postoperative pain intensity and opioid consumption after bunionectomy: results from an interim analysis | |
| RU2022104691A (ru) | Ингибиторы моноаминоксидазы в для применения в предупреждении или лечении карциномы предстательной железы | |
| CY1120669T1 (el) | Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας | |
| Gaughran et al. | Practice update: Cancer in the community part 1: Common pharmaceuticals encountered in community pharmacy |